Authors: Lesley A. Rakowski, Erica A. Lehotzky, Mark Y. Chiang
DOI: 10.1371/journal.pone.0016761
Abstract Summary
Researchers developed a mouse model showing that TLX1, a transcription factor dysregulated in 30-40% of T-cell leukemia cases, drives cancer initiation and maintenance. While suppressing TLX1 or its partner NOTCH pathway temporarily slowed tumor growth, leukemias eventually escaped through alternative oncogenic pathways. This suggests TLX1/NOTCH inhibitors alone won’t cure these leukemias, but could prove valuable in combination therapies.
Why Brain? ðŸ§
Study reveals TLX1 and NOTCH inhibitors alone provide only temporary benefit in T-cell leukemia as tumors develop resistance, but suggests potential value in combination therapy approaches.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
